Publications

Antillon M, Huang C.I, Sutherland S.A, Crump R.E, Bessell P.R, Shaw A.P.M, Tirados I, Picado A, Biéler S, Brown P.E, Solano P, Mbainda S, Darnas J, Wang-Steverding X, Crowley E.H, Peka M, Tediosi F, Rock K.S. Health economic evaluation of strategies to eliminate gambiense human African trypanosomiasis in the Mandoul disease focus of Chad. PLoS Negl Trop Dis. 2023;17(7):e0011396. DOI: 10.1371/journal.pntd.0011396

Antillón M, Li X, Willem L, Bilcke J, RESCEU investigators, Jit M, Beutels P. The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: a semi-parametric, meta-regression approach. PLoS Med. 2023;20(7):e1004250. DOI: 10.1371/journal.pmed.1004250

Burrows H, Antillón M, Gauld J.S, Kim J.H, Mogasale V, Ryckman T, Andrews J.R, Lo N.C, Pitzer V.E. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine. 2023;41(4):965-975. DOI: 10.1016/j.vaccine.2022.12.032

Phillips M.T, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K.M, Gordon M.A, Thindwa D, Paltiel A.D, Yaesoubi R, Pitzer V.E. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infect Dis. 2023;23:143. DOI: 10.1186/s12879-023-08105-2

Antillón M, Huang C.I, Crump R.E, Brown P.E, Snijders R, Mwamba Miaka E, Keeling M.J, Rock K.S, Tediosi F. Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo. Nat Commun. 2022;13:1051. DOI: 10.1038/s41467-022-28598-w

Birger R, Antillón M, Bilcke J, Dolecek C, Dougan G, Pollard A.J, Neuzil K.M, Frost I, Laxminarayan R, Pitzer V.E. Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. Lancet Infect Dis. 2022;22(5):679-691. DOI: 10.1016/S1473-3099(21)00627-7

Rock K.S, Huang C.I, Crump R.E, Bessell P.R, Brown P.E, Tirados I, Solano P, Antillón M, Picado A, Mbainda S, Darnas J, Crowley E.H, Torr S.J, Peka M. Update of transmission modelling and projections of gambiense human African trypanosomiasis in the Mandoul focus, Chad. Infect Dis Poverty. 2022;11:11. DOI: 10.1186/s40249-022-00934-8

Sant Fruchtman C, Fischer F.B, Monzón Llamas L, Tavakkoli M, Cobos Muñoz D, Antillón M. Did COVID-19 policies have the same effect on COVID-19 incidence among women and men? Evidence from Spain and Switzerland. Int J Public Health. 2022;67:1604994. DOI: 10.3389/ijph.2022.1604994

Tavakkoli M, Karim A, Fischer F.B, Monzon Llamas L, Raoofi A, Zafar S, Sant Fruchtman C, de Savigny D, Takian A, Antillón M, Cobos Muñoz D. From public health policy to impact for COVID-19: a multi-country case study in Switzerland, Spain, Iran and Pakistan. Int J Public Health. 2022;67:1604969. DOI: 10.3389/ijph.2022.1604969

Antillón M, Huang C.I, Rock K.S, Tediosi F. Economic evaluation of disease elimination: an extension to the net-benefit framework and application to human African trypanosomiasis. Proc Natl Acad Sci U S A. 2021;118(50):e2026797118. DOI: 10.1073/pnas.2026797118

Davis C.N, Rock K.S, Antillón M, Miaka E.M, Keeling M.J. Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo. BMC Med. 2021;19:86. DOI: 10.1186/s12916-021-01943-4

Baral R, Li X, Willem L, Antillón M, Vilajeliu A, Jit M, Beutels P, Pecenka C. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: estimates from two models. Vaccine. 2020;38(33):5139-5147. DOI: 10.1016/j.vaccine.2020.06.036

Leuba S.I, Yaesoubi R, Antillón M, Cohen T, Zimmer C. Tracking and predicting U.S. influenza activity with a real-time surveillance network. PLoS Comput Biol. 2020;16(11):e1008180. DOI: 10.1371/journal.pcbi.1008180

Li X, Willem L, Antillón M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020;18:82. DOI: 10.1186/s12916-020-01537-6

NTD Modelling Consortium Discussion Group on Gambiense Human African Trypanosomiasis. Insights from quantitative and mathematical modelling on the proposed 2030 goal for gambiense human African trypanosomiasis (gHAT). Gates Open Res. 2020;3:1553. DOI: 10.12688/gatesopenres.13070.1